Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...
BENGALURU, India--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon ® Family of intraocular ...
TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across ...
Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%31-34; PanOptix® Trifocal IOL, implanted over 2.2 ...
GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results